Novocure Secures CE Mark for New Array

Author's Avatar
Nov 11, 2022

Novocure (NASDAQ: NVCR) today announced receipt of CE Mark for its new polymer-based transducer array, called the flex array, designed for more efficient Tumor Treating Fields delivery and greater comfort for patients with glioblastoma. The new arrays are more than 50% thinner and more than 30% lighter compared to current commercial arrays.